Drugs / NRCT-101SR
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT06215144 | Jan 2024 → Oct 2025 | attention deficit-hyperactivity disorder | Neurocentria, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2/3 | NCT05683249 | Feb 2023 → Jan 2024 | attention deficit-hyperactivity disorder | Neurocentria, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NRCT-101SR | “NRCT-101SR is a sustained release formulation.” NCT05683249 ↗ |
| Route | Oral | “receive NRCT-101SR or matching placebo orally twice daily” NCT05683249 ↗ |